Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets.

Frontiers in immunology - 1 Jan 2021

Riddell Shane, Goldie Sarah, McAuley Alexander J, Kuiper Michael J, Durr Peter A, Blasdell Kim R, Tachedjian Mary, Druce Julian D, Smith Trevor R F, Broderick Kate E, Vasan Seshadri S

Abstract excerpt

The ongoing COVID-19 pandemic has resulted in significant global morbidity and mortality on a scale similar to the influenza pandemic of 1918. Over the course of the last few months, a number of SARS-CoV-2 variants have been identified against which vaccine-induced immune responses may be less effective. These "variants-of-concern" have garnered significant attention in the media, with discussion around their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to Antigenic Variation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COVID-19 Vaccines

Share to Ferrets

Share to Immunization, Secondary

Share to Immunogenicity, Vaccine

Share to Spike Glycoprotein, Coronavirus

Share to Vaccination

Source

Open in PubMed Open full text

Identifiers

PMID: 34248993
DOI: 10.3389/fimmu.2021.694857
PMCID: PMC8269317

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets.PMID 34248993Read ↗

Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serumSemantic proximity Read ↗

Sub-optimal Neutralisation of Omicron (B.1.1.529) Variant by Antibodies induced by Vaccine alone or SARS-CoV-2 Infection plus Vaccine (Hybrid Immunity) post 6-monthsSemantic proximity Read ↗

Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 VaccineSemantic proximity Read ↗

Impact of LP.8.1-Adapted mRNA Vaccination on SARS-CoV-2 Variant NeutralisationSemantic proximity Read ↗

SARS-CoV-2 variants: levels of neutralisation required for protective immunitySemantic proximity Read ↗

Breadth of neutralising antibody responses to SARS-CoV-2 variants of concern is augmented by vaccination following prior infection: studies in UK healthcare workers and immunodeficient patientsSemantic proximity Read ↗

Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccinationSemantic proximity Read ↗

INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T cell Activity Against Global SARS-CoV-2 VariantsSemantic proximity Read ↗

INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variantsSemantic proximity Read ↗

The Persistence of Neutralising Antibodies up to 11 months after SARS-CoV-2 Infection in the Southern Region of New ZealandSemantic proximity Read ↗

Digitally Immune-Optimised Next-Generation Influenza H5Nx Vaccination Provides Protection with Broad Cross-Clade Neutralisation Against Global ThreatsSemantic proximity Read ↗

Predicted Symptomatic Effectiveness of Pfizer-BioNTech BNT162b2 Vaccine Against Omicron Variant of SARS-CoV-2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.